PPP2R5C KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 99%.
Images
Key facts
- Cell type
- A-431
- Species or organism
- Human
- Tissue
- Skin
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 99%
Alternative names
2A5G_HUMAN, B' alpha regulatory subunit, B56G, KIAA0044, MGC23064, PP2A B subunit B' gamma isoform, PP2A B subunit B56 gamma isoform, PP2A B subunit PR61 gamma isoform, PP2A B subunit R5 gamma isoform, PP2A B subunit isoform B' gamma, PP2A B subunit isoform B''-gamma, PP2A B subunit isoform B56-gamma, PP2A B subunit isoform PR61-gamma, PP2A B subunit isoform R5-gamma, PR61G, Protein phosphatase 2 regulatory subunit B (B56) gamma isoform, Protein phosphatase 2 regulatory subunit B' gamma, Protein phosphatase 2, regulatory subunit B', gamma isoform, Renal carcinoma antigen NY-REN-29, Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform
Recommended products
PPP2R5C KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 99%.
Key facts
- Cell type
- A-431
- Species or organism
- Human
- Tissue
- Skin
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 99%
- Disease
- Epidermoid Carcinoma
- Concentration
Properties
- Gene name
- PPP2R5C
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage duration
- 1-2 weeks
- Appropriate short-term storage conditions
- -196°C, -80°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The protein phosphatase 2 regulatory subunit B' gamma also known as PPP2R5C is a regulatory component of the protein phosphatase 2A (PP2A) holoenzyme. PPP2R5C has a molecular weight of approximately 59 kDa. This protein shows expression in various tissues including brain kidney spleen and liver. PPP2R5C serves as a modulator by altering the substrate selectivity or catalytic activity of the PP2A core enzyme which consists of a catalytic subunit and a structural subunit.
- Biological function summary
The protein plays a role in mediating cellular processes through its participation as part of the PP2A holoenzyme complex. PP2A regulates various cellular activities including cell cycle progression apoptosis and signal transduction. PPP2R5C contributes to these biological processes by modulating enzyme activity and directing the PP2A holoenzyme to specific subcellular compartments or substrates. This makes PPP2R5C essential for maintaining cellular homeostasis and response to environmental signals.
- Pathways
PPP2R5C functions in key signaling pathways such as the MAPK/ERK pathway and the PI3K/AKT pathway. In the MAPK/ERK pathway PPP2R5C affects phosphorylation states and downstream signaling outcomes. The protein also interacts with other components such as AKT enabling regulation of cellular growth metabolism and survival mechanisms. These interactions define the influence of PPP2R5C on signal propagation and impact the overall cellular response.
- Associated diseases and disorders
Alterations in PPP2R5C have been implicated in cancer and neurodegenerative diseases. In cancer abnormal PP2A activity linked with PPP2R5C affects cell cycle regulation and tumorigenesis interacting with cancer-related pathways and proteins like MYC. In neurodegenerative diseases dysfunctions in signaling mechanisms where PPP2R5C is involved contribute to disease progression affecting proteins related to neuron survival and function. Understanding the role of PPP2R5C in these diseases provides insight into potential therapeutic targets.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Next Generation Sequencing - Human PPP2R5C knockout A-431 cell line (ab269620)
Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift: 99%
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com